Teva Pharmaceutical Industries Limited Stock Price and Value Analysis

Teva Pharmaceutical Industries Limited (NYSE:TEVA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Teva Pharmaceutical Industries Limited to reach your target.

Target type

TEVA Free Cash Flow Trend

Free Cash Flow trendline for TEVA
Free Cash Flow trendline for Teva Pharmaceutical Industries Limited
CSV

Based on historical returns, we believe that Teva Pharmaceutical Industries Limited can grow its free cash at a rate of about 1%. That's positive!

AdvantagesDisadvantagesNeutral
  • This stock is available at a great discount!
  • This company is less known than others.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the TEVA Numbers

TEVA Price
(Teva Pharmaceutical Industries Limited stock price per share)
$38.54
[?] TEVA Fair Price
(based on intrinsic value)
$72.18
[?] TEVA Safety Price (based on a variable margin of safety) $43.31
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 342% higher than other Healthcare stocks
[?] PE Ratio versus Industry 1186% higher than other Drug Manufacturers - General stocks
[?] Cash Yield 13.52%
[?] Free Cash Flow Jitter 68%

Insider Activity Summary

In the six months to 2026-11-22, no insider bought shares, and 9 insiders sold in 11 trades, about $7.1 million.

The six months before that had 0 buys and 39 sales.

Recent Insider Activity

Open-market buys and sells reported by Teva Pharmaceutical Industries Limited's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-08-21 Weiss Amir (Chief Accounting Officer) Sell 6,945 $37.61
2026-08-21 Weiss Amir (Chief Accounting Officer) Sell 2,500 $37.63
2026-08-21 Satchi-Fainaro Ronit Sell 415 $37.25
2026-08-17 Lippman Evan (EVP, Business Development) Sell 18,600 $36.57
2026-08-05 Zaks Tal Zvi Sell 17 $34.87
2026-08-03 Hughes Eric A (See "Remarks") Sell 25,578 $34.88
2026-08-03 Jover Placid (See "Remarks") Sell 12,827 $34.88
2026-06-18 Shields Matthew (EVP, Global Operations) Sell 9,989 $32.19
2026-06-11 Kalif Eliyahu Sharon (EVP, Chief Financial Officer) Sell 106,563 $34.10
2026-06-05 Francis Richard D (President and CEO) Sell 6,153 $34.35

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 27,739,194 shares shorted. With 1,090,551,317 shares available for purchase and an average trading volume over the past 10 trading days of 8,043,120, it would take at least 3.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2016 818686 2,989
2017 818686 1,338
2018 818686 1,637
2019 818686 10.2
2020 818686 510
2021 818686 160
2022 818686 1,017
2023 818686 820
2024 818686 705
2025 818686 1,122

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 3 fiscal years from 2016 to 2025 with positive net income, operating cash flow totaled $6,337 million against net income of $2,156 million, or 2.94 times. Net income was negative in 7 of the 10 years, and those years are left out of the ratio.

In 2025, capital expenditures were $501 million, 30.4% of operating cash flow of $1,649 million, which leaves an estimated $1,148 million after capex. Across the 10 years with reported capex, it averaged 35.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2016 329 3,890 901 11.82
2017 -16,265 2,225 874 n/a
2018 -2,150 2,446 651 n/a
2019 -999 748 525 n/a
2020 -3,990 1,216 578 n/a
2021 417 798 562 1.91
2022 -2,446 1,590 548 n/a
2023 -559 1,368 526 n/a
2024 -1,639 1,247 498 n/a
2025 1,410 1,649 501 1.17

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 3 fiscal years from 2016 to 2018 with dividend or share repurchase facts, estimated free cash flow totaled $5,964 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 3 of those years with dividend payment facts, dividends paid totaled $2,216 million, 37.2% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 3 of those 3 years.

In 2018, dividends paid were $12 million, 0.7% of estimated free cash flow of $1,637 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 2,989 1,303 n/a 1,303 43.6%
2017 1,338 901 n/a 901 67.4%
2018 1,637 12 n/a 12 0.7%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $21,903 million in 2016 and $17,258 million in 2025, a compound annual growth rate of -2.6% over 9 years.

Revenue rose 4.3% from 2024 to 2025.

Our estimated free cash flow was $1,122 million in 2025, 6.5% of revenue. In 2016 the estimated margin was 13.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 21,903 2,989 13.6%
2017 21,853 1,338 6.1%
2018 18,271 1,637 9.0%
2019 16,887 10.2 0.1%
2020 16,659 510 3.1%
2021 15,878 160 1.0%
2022 14,925 1,017 6.8%
2023 15,846 820 5.2%
2024 16,544 705 4.3%
2025 17,258 1,122 6.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $3,556 million against total liabilities of $32,834 million, or 10.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 80.6% of total assets in 2025, compared with 73.5% in 2017, an increase of 7.1 percentage points.

Stockholders equity was $7,914 million in 2025, compared with $18,745 million in 2017, a fall of 57.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 4.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2017 70,615 963 51,870 18,745
2018 60,683 1,782 44,889 15,794
2019 57,470 1,975 42,407 15,063
2020 50,640 2,177 39,579 11,061
2021 47,666 2,165 36,422 11,244
2022 45,932 2,801 37,334 8,598
2023 43,479 3,226 35,353 8,126
2024 39,326 3,300 33,606 5,380
2025 40,748 3,556 32,834 7,914

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $38.54, our model's value equals that price if free cash flow grows an average of -8.7 percent a year over the 10 projection years. Our model assumes 1.5 percent a year for this stock, so the price implies growth of -8.7 percent, which is below the 1.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $6,078 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $30.83 -12.8%
Current price $38.54 -8.7%
20 percent above the current price $46.25 -5.5%
Our model (stored fair price) $72.18 1.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $38.54, Teva Pharmaceutical Industries Limited trades below our safe value estimate of $43.31 and our fair value estimate of $72.18.

Every one of the 10 fiscal years we have for Teva Pharmaceutical Industries Limited under its current filer shows positive free cash flow.

The latest three years average $882 million in free cash flow against $1,988 million for the earliest three, which is a sharp decline.

Year-to-year variability in free cash flow is volatile, measured at 68%.

Our value investing guide explains how to test these numbers against the filings themselves.

We do not have a dividend yield for Teva Pharmaceutical Industries Limited.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 342% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 1186% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Teva Pharmaceutical Industries Limited, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Viatris (VTRS) 22,505 - 2.4% - 2% below
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 818686.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: TEVA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in TEVA

Does Teva Pharmaceutical Industries Limited have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: TEVA

This example shows how we apply the Trendshare checklist to TEVA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 38.54
    • Market cap: $45B
    • EPS: 0.43
  2. Step 2 — Valuation checks

    • P/E: 89.628
    • FCF yield: 13.5%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.